Novartis Buys Protez For Superbug Defense

Image via Wikipedia

Novartis AG strengthened its specialty medicines development portfolio by buying the private, Protez Pharmaceuticals, today for $100M upfront and the potential for up to $400M dependent on meeting certain developmental milestones.
PZ-601, the lead compound, is a broad-spectrum beta-lactam, for the potential treatment of bacterial infections including complicated skin and skin structure infections (cSSSI) [...]